Efficacy and safety of docetaxel (D) vs androgen-receptor signaling inhibitors (ARSi) as second-line therapy (Rx) after progression on alternative ARSi as first-line Rx for patients who are elderly (≥75 years old) with metastatic castration-resistant prostate cancer (mCRPC) in a multicenter international database: A SPARTACUSS–Meet-URO 26 study.
Vincenzo Gennusa(Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo), Edoardo Francini, Ricardo Pereira Mestre(Institute of Oncology Research), Gian Paolo Spinelli(Sapienza University of Rome), Richard M. Lee‐Ying(Alberta Health Services), Sabrina Rossetti(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Pier Vitale Nuzzo(Dana-Farber Cancer Institute), Giuseppe Procopio(Fondazione IRCCS Istituto Nazionale dei Tumori), Ugo De Giorgi(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Anna Patrikidou(Institut Gustave Roussy), Calogero Saieva(Istituto per lo Studio e la Prevenzione Oncologica), Giuseppe Fornarini(Ospedale Policlinico San Martino), Loana Bueno Valença(D’Or Institute for Research and Education), Daniele Santini(Policlinico Umberto I), Antonio Russo(University of Palermo), Christopher Sweeney(Harvard University), Giuseppe Fotia(Fondazione IRCCS Istituto Nazionale dei Tumori), Daniel Yick Chin Heng(University of Calgary), Elisa Zanardi(Ospedale Policlinico San Martino)
Cited by 1
Related Papers
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2020|786
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Oncology|2020|502